Fermenta Biotech
FERMENTA NSE
Fermenta Biotech
HealthcareNSE: FERMENTA BSE: 506414 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹1,393 Cr
Volatility
Moderate
P/E Ratio
23.4
EBITDA
₹122 Cr
Return on Equity
17.54%
Debt to Equity
0.28
Book Value
₹138.15
52W High
₹580.45
52W Low
₹248.85
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- The company has delivered a poor sales growth of 6.85% over past five years.
- Company has a low return on equity of 12.6% over last 3 years.
- Working capital days have increased from 48.7 days to 96.2 days
Growth Rate
Revenue Growth
13.82% lower than
3Y
Net Income Growth
-7.98% lower than
3Y
Cash Flow Change
127% higher than
3Y
ROE
-17.69% lower than
3Y
ROCE
1.12%
EBITDA Margin (Avg.)
-11.71% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82.45 | 56.91 | 98.97 | 97.34 | 78.13 | 95.03 | 156 | 140 | 136 | 130 | 137 | 122 | 122 |
| Expenses | 71.52 | 70.82 | 73.84 | 91.96 | 77.33 | 76.25 | 103 | 103 | 108 | 104 | 112 | 102 | 104 |
| Operating Profit | 10.93 | -13.91 | 25.13 | 5.38 | 0.8 | 18.78 | 53.27 | 36.95 | 28.24 | 26.64 | 24.96 | 20 | 18.06 |
| OPM % | 13.26% | -24.44% | 25.39% | 5.53% | 1.02% | 19.76% | 34.04% | 26.42% | 20.73% | 20.46% | 18.17% | 16.45% | 14.83% |
| Other Income | 2.01 | -5.53 | 2.52 | 5.38 | 2.82 | 2.88 | 2.23 | 3.89 | 8.77 | 5.43 | 0.92 | 14.14 | 4.37 |
| Interest | 4.78 | 3.69 | 5.19 | 3.39 | 3.43 | 3.69 | 4.08 | 2.99 | 3.11 | 2.58 | 3.03 | 2.82 | 2.54 |
| Depreciation | 5.95 | 5.93 | 6.38 | 6.46 | 6.12 | 6.15 | 6.08 | 5.86 | 5.81 | 5.41 | 5.37 | 5.11 | 5.2 |
| PBT | 2.21 | -29.06 | 16.08 | 0.91 | -5.93 | 11.82 | 45.34 | 31.99 | 28.09 | 24.08 | 17.48 | 26.21 | 14.69 |
| Tax % | 0% | 0% | 37.81% | 884.62% | 0% | 5.92% | 16.43% | -4.19% | 23.07% | 25.17% | 31.24% | 29.03% | 35.13% |
| Net Profit | 2.21 | -29.07 | 9.99 | -7.14 | -5.93 | 11.12 | 37.89 | 33.32 | 21.6 | 18.03 | 12.02 | 18.6 | 9.53 |
| EPS in Rs | 0.62 | -9.7 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 | 3.31 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 523 | 511 |
| Expenses | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 422 | 421 |
| Operating Profit | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 101 | 90 |
| OPM % | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 19% | 18% |
| Other Income | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 29 | 25 |
| Interest | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 | 11 |
| Depreciation | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 | 21 |
| PBT | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 96 | 82 |
| Tax % | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | 27% | — |
| Net Profit | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 70 | 58 |
| EPS in Rs | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 24.39 | 20.28 |
| Div. Payout % | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% | 15% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 |
| Reserves | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 392 |
| Borrowings | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 113 |
| Other Liabilities | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 128 |
| Total Liabilities | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
| Fixed Assets | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 220 |
| CWIP | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 |
| Investments | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 414 |
| Total Assets | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | 93 |
| Investing | -18 | -13 | 7 | -101 | -97 | -44 | -41 | -26 | -55 | -16 | 0 | -43 |
| Financing | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 | -42 |
| Net Cash Flow | -2 | 1 | -4 | 47 | 6 | -57 | 21 | -4 | 19 | -1 | -10 | 8 |
| Free Cash Flow | -20 | -25 | -17 | 42 | 55 | -34 | 7 | 6 | 76 | 86 | 38 | 63 |
| CFO/OP | 119 | 35 | 35 | 83 | 79 | 73 | 92 | 85 | 610 | 370 | 38 | 108 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 | 78 |
| Inventory Days | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 285 | 290 |
| Days Payable | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 178 | 147 |
| Cash Conversion Cycle | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 181 | 221 |
| Working Capital Days | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 | 96 |
| ROCE % | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | 0% | 3% | 23% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fermenta Biotech insights
62 extracted metrics + investor summaries across FY15–FY26.
Documents
1
Clarification sought from Fermenta Biotech Ltd
16 Jul - Exchange has sought clarification from Fermenta Biotech Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors … 16 Jul - Exchange has sought clarification from Fermenta Biotech Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors …
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 May - Publication of IEPF related notice for equity shareholders 7 May - Publication of IEPF related notice for equity shareholders
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
28 Apr - Fermenta Biotech confirms it is not a Large Corporate under SEBI circulars for FY2025-26. 28 Apr - Fermenta Biotech confirms it is not a Large Corporate under SEBI circulars for FY2025-26.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
28 Apr - Fermenta Biotech says it is not a Large Corporate; FY2025-26 borrowing disclosure filed. 28 Apr - Fermenta Biotech says it is not a Large Corporate; FY2025-26 borrowing disclosure filed.
5
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Apr - Newspaper Publication for Notice for Special window for Transfer and Dematerialisation of Physical Securities. 28 Apr - Newspaper Publication for Notice for Special window for Transfer and Dematerialisation of Physical Securities.
Frequently Asked Questions about Fermenta Biotech
What does Fermenta Biotech Ltd do?
Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Where is Fermenta Biotech Ltd (506414) listed?
Fermenta Biotech Ltd trades as FERMENTA on the NSE and under code 506414 on the BSE.
Which sector does Fermenta Biotech Ltd belong to?
Fermenta Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Fermenta Biotech Ltd?
Fermenta Biotech Ltd has a market capitalisation of ₹1,393 Cr, which places it in the Small Cap band.
What is the PE ratio of Fermenta Biotech Ltd?
Fermenta Biotech Ltd trades at a PE ratio of 23.40, against a book value of ₹138.15 per share.
What is the 52-week high and low of Fermenta Biotech Ltd?
Over the last 52 weeks Fermenta Biotech Ltd has traded between ₹248.85 and ₹580.45.
Does Fermenta Biotech Ltd pay dividends?
Fermenta Biotech Ltd has a dividend yield of 0.78%.
What is the Return on Equity (ROE) of Fermenta Biotech Ltd?
Fermenta Biotech Ltd reported a return on equity of 17.54%. Its debt-to-equity ratio is 0.28.
Company Information
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506414.md for Fermenta Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.